战略与国际研究中心-A-Significant-First-Step,-as-UN-Member-States-Declare-Antimicrobial-Resistance-a-Global-Priority_20页_2mb

Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations

Core Content

The Review on Antimicrobial Resistance, chaired by Jim O'Neill, highlights the growing global threat of antimicrobial resistance (AMR) and its potential to cause profound health and economic consequences if not addressed. The report outlines five key themes to guide international action, emphasizing the need for a coordinated, multidisciplinary response.

Main Points and Key Information

1. What is Antimicrobial Resistance?

• AMR occurs when bacteria and other pathogens evolve to resist the drugs used to treat them.
• It is a global problem that affects both high-income and low-income countries.
• Resistance is not limited to bacteria but includes all microbes that can mutate to become drug-resistant.

2. Economic Impact of AMR

• Current Impact: In Europe and the US, AMR causes at least 50,000 deaths annually.
• Future Projections: If AMR is not tackled, the report estimates:
  • 300 million premature deaths over the next 35 years.
  • A reduction in global GDP by 2% to 3.5% by 2050.
  • A potential economic loss of 60 to 100 trillion USD between now and 2050.
  • 10 million additional deaths annually by 2050 due to rising resistance.
• Secondary Economic Effects: The loss of economic output from medical procedures that rely on effective antimicrobials, such as:
  • Cesarean sections (contribute ~2% to global GDP)
  • Joint replacements (~0.65%)
  • Cancer treatments (over 0.75%)
  • Organ transplants (~0.1%)
  • These procedures collectively contribute ~4% to global GDP, with a potential total loss of 210 trillion USD by 2050.

3. Key Drivers of AMR Impact

• E. coli, Klebsiella pneumoniae, and Staphylococcus aureus are major contributors to AMR-related mortality and economic loss.
• Malaria and TB are the most significant in terms of human fatalities, while E. coli has the greatest economic impact.
• Regional Variations: Countries with high rates of malaria, TB, and HIV are most at risk, especially in Africa, India, Nigeria, and Indonesia.

4. Causes of AMR

• Overuse and Misuse: Widespread use of antimicrobials, especially over-the-counter availability, contributes to resistance.
• Counterfeit Drugs: Poor quality drugs in some regions further exacerbate the problem.
• Global Travel and Trade: The speed and volume of international movement increase the spread of resistant pathogens.
• Lack of Data: Reliable global data on infections and resistance is scarce, leading to broad-brush estimates rather than precise forecasts.

5. International Action and Solutions

• Need for Coherent Global Strategy: AMR is a transnational issue requiring unified efforts across drug regulation, human, animal, and environmental use.
• Innovation and Research: The report encourages investment in new antimicrobial drugs, vaccines, and alternative therapies.
• Collaboration: It calls for international cooperation, especially among OECD and non-OECD countries, and highlights existing frameworks such as the WHO and EU-US partnerships.
• Technological Advances: Genetics, genomics, and computer science can improve detection, diagnosis, and reporting of resistant infections, enabling faster responses.

Future Work and Optimism

• The Review will propose a package of international actions by summer 2016.
• There is cause for optimism:
  • A vibrant research and innovation community exists globally.
  • International governance frameworks are already in place, with the WHO leading a global action plan.
  • Philanthropy and public-private partnerships are showing promise in accelerating solutions.
• Economic Incentives: Tackling AMR aligns with the growth objectives of low and middle-income countries by improving sanitation and health infrastructure.

Conclusion

• AMR is not just a health crisis but also a major economic threat.
• The cost of inaction is far greater than the cost of action.
• Immediate and coordinated global efforts are essential to preserve the progress of modern medicine and avoid a return to the "dark age of medicine" where common infections and surgeries become deadly.

References

• World Health Organization (WHO) Global Tuberculosis Report 2014
• Van Boeckel, T P et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet Infectious Diseases, 2014.
• www.yanbaoke.com (used as a source for some data and references)
• www.who.int/mediacentre/factsheets/ (sources for health-related data)

Summary

The Review on Antimicrobial Resistance underscores the critical importance of addressing AMR to protect both human health and global economic stability. By highlighting the potential for profound mortality and GDP loss, it calls for international collaboration, innovation, and investment in better surveillance and infrastructure. The report provides a call to action for governments, the scientific community, and the private sector to act now and prevent a global crisis.